Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06433947 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma, sponsored by Opna Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 10
- Study locations
NCT06433947 is a Phase 1 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma that is actively recruiting participants, run by Opna Bio. The registered enrollment target is 130 participants, above the 46-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (183% higher). The trial reports 10 study locations across 9 states.
The verdict
NCT06433947, a Phase 1 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma, is actively recruiting participants, sponsored by Opna Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 10
- Study locations
Study Summary
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
Conditions Studied
Interventions
- DRUG OPN-6602
- DRUG Dexamethasone
Study Locations (10)
Michigan
- Karmanos Cancer Institute - Detroit
- START Midwest - Grand Rapids
Arizona
- Banner MD Anderson - Gilbert
California
- Stanford Cancer Institute - Stanford
Georgia
- Emory Winchip Cancer Center - Atlanta
Kansas
- University of Kansas Clinical Research Center - Westwood
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- University of Rochester Medical Center - Rochester
Utah
- Huntsman Cancer Center Institute University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06433947
The ClinicalTrials.gov registry entry for NCT06433947 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 46-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (183% higher). The listed sponsor is Opna Bio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which OPN-6602 is the first listed.
NCT06433947 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Michigan, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06433947 about?
NCT06433947 is a clinical study titled "Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma". Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
What is the current status of trial NCT06433947?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2024-08-22. Estimated completion is 2026-07.
What conditions does trial NCT06433947 study?
This clinical trial studies the following conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma.
What interventions are being tested in trial NCT06433947?
The interventions under investigation include: OPN-6602 (DRUG), Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT06433947?
This trial is sponsored by Opna Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06433947 being conducted?
This trial has 10 study locations across Arizona, California, Georgia, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
RECRUITING · Phase 1
-
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.